FAM84B-edited tumor-infiltrating lymphocytes

FAM84B-edited tumor-infiltrating lymphocytes (TILs) are an adoptive cell therapy product consisting of autologous lymphocytes that have been genetically modified to knock out or precisely edit the FAM84B gene. Developed using the T-Editor platform—a CRISPR-mediated engineering system—these cells are designed to overcome the immunosuppressive tumor microenvironment. FAM84B was identified through transcriptomic profiling of responders versus non-responders in TIL clinical trials as a novel inhibitory regulator; its depletion results in increased cytolytic activity, enhanced memory phenotypes, and elevated interferon-gamma (IFN-γ) secretion. Preclinical studies in patient-derived xenograft (PDX) models have demonstrated that FAM84B-edited TILs exhibit superior tumor growth inhibition compared to standard TIL therapies, making them a promising candidate for the treatment of various solid tumors.

Other names

FAM84B-KO TILsFAM-84B-KO TILsFAM 84B-KO TILsFAM84B base-edited TILsFAM-84B base-edited TILsFAM 84B base-edited TILs